VisiQuate Acquires Artiva HCx for Revenue Cycle Workflows

Buying a healthcare workflow means inheriting a workday already in progress. VisiQuate has taken on that responsibility through its acquisition of Finvi's Artiva HCx business, bringing an established revenue cycle platform, its operating team and its clients into the Santa Rosa, California technology company.

The companies announced the completed transaction on November 4, 2026. Financial terms were undisclosed. VisiQuate plans to connect its revenue intelligence and automation with software already used for insurance follow-up, denial management and collections, while Finvi concentrates its resources on the collections market.

For healthcare operators, the meaningful question sits inside the work itself: how does a recommendation become an account someone can resolve? This acquisition gives VisiQuate more of that journey to develop, and gives the people using Artiva HCx a role in shaping the integration priorities.

What VisiQuate acquired from Finvi

Artiva HCx is the business being acquired, rather than all of Finvi. That distinction matters for customers whose technology relationships extend across several products: ownership of the healthcare revenue cycle operation changes, while Finvi continues serving its other customers. The deal brings the HCx workflow platform, the experienced team behind it and its client relationships to VisiQuate.

Finvi's sale announcement describes a sharper concentration on third-party collections under CEO Laura Granahan. Finvi says its collections customers are unaffected by the transaction and that the companies will jointly support HCx clients during the transition. Customers using HCx alongside other Finvi products remain part of that support commitment, a practical detail that deserves more attention than the usual acquisition vocabulary.

Neither announcement discloses a purchase price, a cash-and-stock breakdown or an earnout. The companies describe the sale as completed, but do not provide a separate legal closing date or a regulatory approval account. Those omissions leave the transaction's economics outside public view; they also keep the story focused on the operating assets that the buyer actually identified.

The acquired business should not be confused with a newly funded standalone startup. Artiva HCx is a healthcare revenue cycle platform moving between owners, with existing users and established workflows. Its current official product information sits on VisiQuate's website, while Finvi remains the seller and a transition partner.

Bringing intelligence closer to account work

VisiQuate's revenue cycle tools prioritize opportunities by value and root cause, track payer policy changes and identify revenue at risk. Artiva HCx supplies the workflow side: routing and managing the insurance follow-up, denied claims and collections work through which those opportunities can move toward resolution. Bringing the capabilities under one owner creates room to connect a recommendation with the next operational step.

The distinction is familiar to anyone responsible for a queue. A ranked account still needs an appropriate action, a responsible person or automation, and a way to understand the result. The commercial value of the combination lies in making those decisions useful inside the workflow healthcare teams already run. That is an interpretation of the product fit, rather than a claim that every planned connection is available today.

VisiQuate's customer transition page says it is investing in both product suites and their integration, starting with AI and automation that reduce repetitive tasks. It also says the combined offering works alongside existing electronic health record systems. The proposed route into the customer organization therefore begins with the systems and practices already there.

The operating team matters to this design. People who have built and supported account workflows understand where a payer rule, missing document or unusual case changes the next step. Acquiring that expertise gives product development a closer relationship with the exceptions its users handle, even as the integration roadmap is still being shaped.

An established analytics company expands its remit

Brian Robertson founded VisiQuate in 2009 and remains its CEO. His background includes co-founding MedeAnalytics and serving in operating, technology and innovation leadership roles. VisiQuate's current CTO, Vitaliy Gavrylenko, leads its engineering organization, placing the integration inside an established healthcare technology business rather than a newly assembled product venture.

The ownership context reaches back to October 2024, when Accel-KKR announced its acquisition of VisiQuate. The investment firm backed a company already selling revenue cycle analytics, workflow and automation to healthcare organizations. Its support is relevant to the expansion strategy, although the current announcements disclose no new financing amount for the HCx purchase.

VisiQuate also acquired Etyon in July 2025, adding revenue cycle machine learning, algorithms and data-tokenization capabilities. The sequence shows the buyer assembling complementary technology and expertise around its healthcare focus. HCx extends that effort into the established processes through which customers manage account work.

For Finvi, the same transaction concentrates attention and investment on collections. For VisiQuate, it broadens the healthcare operation it can serve. Those directions explain the strategic fit without requiring a speculative market-share claim or an assumption about how quickly the combined business will improve financial performance.

Customers will help choose the integration priorities

VisiQuate says current clients of both businesses will retain support for their existing products and contracts, and will help shape product and integration priorities. That arrangement places customer operating knowledge inside the development conversation. The people who need a follow-up resolved have a different view of useful automation from someone reviewing a feature list.

The company's stated human-in-the-loop approach lets organizations govern what work goes to a team member and what automation can resolve. For buyers, that makes the allocation of responsibility part of the product discussion. A health system needs to understand where staff judgment stays involved, what information supports an action and how its existing processes will accommodate a new capability.

The announcements provide no quantified results for the newly combined offering or a dated schedule for completing its integration. Expected reductions in manual effort and faster revenue recovery remain goals. Customers can assess those goals through their own account work, using the product and support relationships that continue through the ownership change.

HCx users will bring live operating priorities to that conversation while VisiQuate decides what to build across the two suites. An insurance follow-up queue keeps producing cases during an integration programme, and those cases give the acquired team and its clients specific work to put in front of their new product colleagues.